CytoMed Therapeutics (GDTC) Stock Chart & Stock Price History $2.14 +0.12 (+5.94%) As of 09:43 AM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock CytoMed Therapeutics Stock Price Performance The CytoMed Therapeutics (GDTC) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 2.88%, with a year-to-date return of -37.06%. In the past month, the stock has decreased 7.12%, reflecting recent market activity. As of the latest close, CytoMed Therapeutics traded at $2.12 with a market cap of $23.19 million and volume of 2,972 shares. Receive GDTC Stock News and Ratings via EmailSign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+4.39%1 Month Performance-7.12%3 Month Performance-17.69%Year-To-Date Performance-37.06%1 Year Performance+2.88% GDTC Stock Chart for Thursday, June, 12, 2025 GDTC Chart by TradingView CytoMed Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/11/2025$2.08$2.12+2.17%$2.07$2.022,972 shs$23.19 million06/10/2025$2.12$2.08-1.89%$2.13$2.053,775 shs$22.70 million06/09/2025$2.05$2.12+3.17%$2.09$2.012,670 shs$23.14 million06/06/2025$2.05$2.05-0.05%$2.14$2.041,218 shs$22.43 million06/05/2025$2.06$2.05-0.44%$2.12$2.018,014 shs$22.44 million06/04/2025$2.16$2.06-4.63%$2.16$2.0021,517 shs$22.54 million06/03/2025$2.34$2.16-7.69%$2.36$2.1616,609 shs$23.63 million06/02/2025$2.32$2.34+0.86%$2.36$2.341,005 shs$25.60 million05/30/2025$2.32$2.32$2.32$2.32473 shs$25.38 million05/29/2025$2.33$2.32-0.22%$2.35$2.2517,114 shs$25.38 million Get the Latest News and Ratings for GDTC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/28/2025$2.39$2.33-2.52%$2.37$2.217,560 shs$25.44 million05/27/2025$2.21$2.39+8.16%$2.45$2.2455,037 shs$26.09 million05/26/2025$2.21$2.21$2.32$2.205,479 shs$24.12 million05/23/2025$2.27$2.21-2.65%$2.32$2.205,479 shs$24.12 million05/22/2025$2.10$2.27+7.86%$2.33$2.191,855 shs$24.78 million05/21/2025$2.01$2.10+4.48%$2.24$2.103,043 shs$22.97 million05/20/2025$2.25$2.01-10.67%$2.23$2.0117,441 shs$21.99 million05/19/2025$2.26$2.25-0.44%$2.38$2.193,787 shs$24.62 million05/16/2025$2.34$2.26-3.42%$2.38$2.193,787 shs$24.72 million05/15/2025$2.35$2.34-0.43%$2.33$2.301,492 shs$25.60 million05/14/2025$2.27$2.35+3.52%$2.35$2.301,580 shs$25.71 million05/13/2025$2.30$2.27-1.48%$2.30$2.263,847 shs$24.83 million05/12/2025$2.22$2.30+3.78%$2.60$2.284,669 shs$25.21 million Related Companies COYA Stock Chart ENTX Stock Chart LXEO Stock Chart BMEA Stock Chart ORMP Stock Chart UNCY Stock Chart ANIX Stock Chart CHRS Stock Chart MIST Stock Chart JSPR Stock Chart Receive GDTC Stock News and Ratings via EmailSign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:GDTC) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
